Loading publications…
The last 5 uploaded publications
Regulation of PRMT5–MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma
Shatha AbuHammad, Carleen Cullinane, Claire Martin, Zoe Bacolas, Teresa Ward, Huiqin Chen, Alison Slater, Kerry Ardley, Laura Kirby, Keefe T. Chan, Natalie Brajanovski, Lorey Smith, Aparna D. Rao, Emily J. Lelliott, Margarete Kleinschmidt, Ismael A. Vergara, Anthony T. Papenfuss, Peter K. H. Lau, Prerana Ghosh, Sue Haupt, Ygal Haupt, Elaine Sanij, Gretchen Poortinga, Richard B. Pearson, Hendrik Falk, David J. Curtis, Paul A. Stupple, Mark Devlin, Ian P. Street, Michael A. Davies, Grant A. McArthur, Karen E. Sheppard (2019). Regulation of PRMT5–MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma. , 116(36), DOI: https://doi.org/10.1073/pnas.1901323116.
Article62 days agoCHARLI: A phase Ib/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanoma.
Peter K. H. Lau, S.J. Harris, Melissa Eastgate, Damien Kee, Andrew Mant, Louise M. Nott, Craig Gedye, Andrisha Jade Inderjeeth, Craig Underhill, Alison M. Weppler, Roslyn Wallace, Belinda Lee, George Au‐Yeung, Narelle Williams, Daniel Ariza Ospino, Louise Gonzales, Mark Shackleton, Serigne Lo, Grant A. McArthur, Shahneen Sandhu (2023). CHARLI: A phase Ib/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanoma.. , 41(16_suppl), DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.9525.
Article62 days agoMelanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)
Peter K. H. Lau, Breon Feran, Lorey Smith, Arian Lasocki, Ramyar Molania, Kortnye Smith, Alison M. Weppler, Christopher Angel, Damien Kee, Prachi Bhave, Belinda Lee, Richard J. Young, Amir Iravani, Hanxian Aw Yeang, Ismael A. Vergara, David L. Kok, Kate Drummond, Paul J. Neeson, Karen E. Sheppard, Anthony T. Papenfuss, Benjamin Solomon, Shahneen Sandhu, Grant A. McArthur (2021). Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES). , 9(10), DOI: https://doi.org/10.1136/jitc-2021-002995.
Article62 days agoFDG-PET metabolic tumor volume in advanced melanoma treated with ipilimumab and nivolumab (ipi/nivo).
Amir Iravani, Roslyn Wallace, Serigne Lo, Anna Galligan, Alison M. Weppler, George Au‐Yeung, Damien Kee, Peter K. H. Lau, Benjamin Brady, Belinda Lee, Grant A. McArthur, Shahneen Sandhu, Rodney J. Hicks (2020). FDG-PET metabolic tumor volume in advanced melanoma treated with ipilimumab and nivolumab (ipi/nivo).. , 38(15_suppl), DOI: https://doi.org/10.1200/jco.2020.38.15_suppl.10041.
Article62 days ago1079MO Progression of BRAF mutant CNS metastases are associated with a transcriptional network bearing similarities with the innate PD-1 resistant signature (IPRES)
Peter K. H. Lau, Breon Feran, Lorey Smith, Arian Lasocki, Ramyar Molania, Kortnye Smith, Alison M. Weppler, Christopher Angel, Damien Kee, Prachi Bhave, Belinda Lee, Han Xian Aw Yeang, Ismael A. Vergara, David L. Kok, Katharine J. Drummond, Paul J. Neeson, Karen E. Sheppard, Anthony T. Papenfuss, Shahneen Sandhu, Grant A. McArthur (2020). 1079MO Progression of BRAF mutant CNS metastases are associated with a transcriptional network bearing similarities with the innate PD-1 resistant signature (IPRES). , 31, DOI: https://doi.org/10.1016/j.annonc.2020.08.1203.
Article62 days ago